Recursion Pharmaceuticals, Inc. (RXRX) NASDAQ

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Najat Khan	CEO, President & Director	903,460	1984
Ben R. Taylor	Chief Financial Officer & President of Recursion UK	751,492	1977
Vicki L. Goodman	Chief Medical Officer	793,399	1971
David J. Mauro	Advisor	793,399	1965
Christopher C. Gibson	Co-Founder, Chairman & Interim Executive Advisor	952,508	1983
Sid Jain	Senior Vice President of Clinical Development & Data Science	0	N/A
Erica Fox	Chief People and Impact Officer	0	N/A
Kristen Rushton	Chief Operating Officer	0	N/A
David Hallett	Chief Scientific Officer	0	1969
Elizabeth Bruckheimer	Vice President of Clinical Development	0	N/A
Ryan Kelly	Chief Communications Officer	0	N/A
Benjamin Mabey	Chief Technology Officer	0	1983
Matthew Kinn	Chief Business Officer	0	N/A
Nathan Hatfield	Chief Legal Officer & Corporate Secretary	0	N/A

Name

Title

Pay

Year Born

Najat Khan

CEO, President & Director

903,460

1984

Ben R. Taylor

Chief Financial Officer & President of Recursion UK

751,492

1977

Vicki L. Goodman

Chief Medical Officer

793,399

1971

David J. Mauro

Advisor

793,399

1965

Christopher C. Gibson

Co-Founder, Chairman & Interim Executive Advisor

952,508

1983

Sid Jain

Senior Vice President of Clinical Development & Data Science

N/A

Erica Fox

Chief People and Impact Officer

N/A

Kristen Rushton

Chief Operating Officer

N/A

David Hallett

Chief Scientific Officer

1969

Elizabeth Bruckheimer

Vice President of Clinical Development

N/A

Ryan Kelly

Chief Communications Officer

N/A

Benjamin Mabey

Chief Technology Officer

1983

Matthew Kinn

Chief Business Officer

N/A

Nathan Hatfield

Chief Legal Officer & Corporate Secretary

N/A

Description

Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering. Their developmental pipeline features several clinical-stage compounds: REC-994, which is advancing through Phase IIa trials for cerebral cavernous malformation; REC-3599, currently in Phase I trials for GM2 gangliosidosis; REC-2282, aimed at treating neurofibromatosis type 2; and REC-4881, intended for familial adenomatous polyposis. Beyond these, Recursion maintains a comprehensive preclinical portfolio. This includes REC-3964 for Clostridium difficile colitis, REC-64917 targeting neural or systemic inflammation, and REC-65029 for HRD-negative ovarian cancer. Further preclinical candidates are REC-648918, designed to enhance anti-tumor immunity; REC-2029 for wnt-mutant hepatocellular carcinoma; REC-14221 for various solid and hematological malignancies; and REC-64151, focused on addressing immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has established strategic collaborations and agreements with partners such as Bayer AG, the University of Utah Research Foundation, the Ohio State Innovation Foundation, Chromaderm, Inc., and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.